Vasopressin is the body’s antidiuretic hormone, and a synthetic copy is a prescription drug for shock. This guide covers its structure, mechanism, FDA approvals, key trials and label warnings. Sources checked November 17, 2026.
Quick answer: Vasopressin is a natural peptide hormone and an FDA-approved prescription drug. It narrows blood vessels through V1 receptors and saves water through V2 receptors in the kidney. FDA approved Vasostrict to raise blood pressure in adults with vasodilatory shock.
Vitrapep does not sell vasopressin; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is vasopressin?
Vasopressin is a natural hormone. ChEBI, quoted in PubChem, calls arginine vasopressin “the predominant form of mammalian vasopressin (antidiuretic hormone).” It describes a nonapeptide, or chain of nine amino acids, with arginine at position 8. A disulfide bond links the cysteines at positions 1 and 6, which closes a ring (PubChem CID 644077).
PubChem lists its formula as C46H65N15O12S2 and its molecular weight as 1084.2 g/mol. The Vasostrict label calls vasopressin “a polypeptide hormone” and describes the product as synthetic arginine vasopressin (Vasostrict label). As a drug, it is a vasopressor, a medicine that raises blood pressure. For background, see our overview of peptide hormones.
FDA approved Vasostrict on April 17, 2014. Drugs@FDA classes that approval as “Type 7 - Drug Already Marketed without Approved NDA” (Drugs@FDA, NDA 204485). An older Parke-Davis application, Pitressin Tannate (NDA 003402), is listed as discontinued, with no approval date shown (Drugs@FDA, NDA 003402). FDA approved further vasopressin products from American Regent in 2020, Baxter in 2023 and Long Grove in 2024 (Drugs@FDA data).
Vasopressin: key facts
| Fact | Detail |
|---|---|
| Structure | Nine amino acids; arginine at position 8; disulfide bond between cysteines 1 and 6 |
| Class | Peptide hormone; vasopressor acting on V1 and V2 receptors |
| Molecular formula | C46H65N15O12S2 (PubChem) |
| Molecular weight | 1084.2 g/mol (PubChem) |
| First FDA approval | Earliest dated: Vasostrict, April 17, 2014 (NDA 204485); Pitressin Tannate listed with no date |
| Approved brands | Vasostrict; other approved products sold as vasopressin; Pitressin Tannate (discontinued) |
How does vasopressin work?
The Vasostrict label describes two receptor actions. Vasopressin binds V1 receptors on the smooth muscle of blood vessels. These receptors work through the Gq/11 and phospholipase C pathway, which releases calcium inside the cell and makes the vessel contract. Vasopressin also binds V2 receptors in the kidney, which are coupled to adenylyl cyclase. That action reduces urine output.
The label adds that vasopressin narrows most vascular beds, including those of the gut, kidney and skin. In vasodilatory shock, it raises vascular resistance and blood pressure and lowers the need for norepinephrine. It tends to slow the heart rate and reduce cardiac output. The label gives an apparent half-life of 10 minutes or less in shock (see peptide half-life).
What is vasopressin approved for?
The Vasostrict label states one indication. Vasostrict is approved to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasodilatory shock means dangerously low blood pressure caused by widened blood vessels, as in septic shock. The label’s initial U.S. approval year is 2014.
The label’s clinical studies section is short. It says vasopressin raised systolic and mean blood pressure in 7 studies in septic shock and 8 in vasodilatory shock after heart surgery.
What did the key trials of vasopressin show?
VASST (2008). This randomized, double-blind trial compared vasopressin with norepinephrine in 778 people with septic shock already on norepinephrine (Russell et al., 2008; ISRCTN94845869). The primary outcome, 28-day mortality, was 35.4% with vasopressin and 39.3% with norepinephrine (P = 0.26). Serious adverse events were similar, at 10.3% and 10.5%. The authors concluded that vasopressin did not reduce mortality.
VANISH (2016). This 2×2 factorial, double-blind trial randomized 409 adults with septic shock in 18 UK intensive care units (Gordon et al., 2016; ISRCTN20769191). It tested early vasopressin against norepinephrine, with hydrocortisone or placebo as a second factor. Vasopressin did not improve kidney failure-free days, the primary outcome. Among survivors, 57.0% on vasopressin and 59.2% on norepinephrine never developed kidney failure.
VAM-IHCA (2021). This Danish placebo-controlled trial tested vasopressin plus methylprednisolone during in-hospital cardiac arrest (NCT03640949). Among 501 analyzed patients, return of spontaneous circulation occurred in 42% versus 33% with placebo (Andersen et al., 2021). Survival at 30 days did not differ significantly: 9.7% versus 12%. Cardiac arrest is not a labeled indication. All three are human trials.
What side effects does the vasopressin label list?
The Vasostrict label has no boxed warning. It lists two warnings. The first is worsening cardiac function, because “a decrease in cardiac index may be observed.” The second is reversible diabetes insipidus after the drug is stopped, with excess dilute urine and high blood sodium. The label notes that some patients may need vasopressin again or desmopressin to correct this.
The label names the most common adverse reactions as decreased cardiac output, slow heart rate, fast heart rhythms, hyponatremia and ischemia. Ischemia means reduced blood flow, here to the heart, gut, skin or fingers and toes. Other listed reactions include low platelets, bleeding, atrial fibrillation, right heart failure, raised bilirubin and acute kidney insufficiency. The label says these come from voluntary reports, so their frequency cannot be reliably estimated.
What is the regulatory status of vasopressin, and is it used in research?
Vasopressin is a prescription drug in the United States. Drugs@FDA lists the marketed Vasostrict products with prescription status. FDA’s Drug Safety Communications page lists no communication naming vasopressin in its titles. The list runs from January 14, 2020, to November 9, 2026 (FDA).
WADA’s 2026 Prohibited List does not name vasopressin. Its S5 section, Diuretics and Masking Agents, names the analog desmopressin. S5 also covers “other substances with a similar chemical structure or similar biological effect(s).” Our guide to peptides on the 2026 WADA list explains the sections.
In research, ChEBI lists vasopressin’s roles as a cardiovascular drug, a hematologic agent and a mitogen, meaning a substance that triggers cell division. Human trials continue in critical care, such as the NoVa sepsis trial described below.
Frequently asked questions about vasopressin
Is vasopressin a peptide?
Yes. It is a chain of nine amino acids, closed into a ring by a disulfide bond. See what peptides are.
Is vasopressin the same as antidiuretic hormone?
Yes. ChEBI describes arginine vasopressin as the predominant form of mammalian vasopressin, also called antidiuretic hormone.
How is vasopressin different from desmopressin?
Desmopressin is a synthetic analog of vasopressin. The two differ in structure, receptor action and approved uses. Our desmopressin guide covers the differences, with its own label sources.
Does vasopressin have a boxed warning?
No. The Vasostrict label has none. Its warnings cover worsening cardiac function and reversible diabetes insipidus.
What to know now
- Structure: a nine-amino-acid ring peptide; C46H65N15O12S2, 1084.2 g/mol.
- Approval: Vasostrict, April 17, 2014, the earliest dated approval in Drugs@FDA.
- Approved use: raising blood pressure in adults with vasodilatory shock despite fluids and catecholamines.
- Trials: VASST and VANISH found no mortality or kidney benefit over norepinephrine.
- Label safety: no boxed warning; warnings on cardiac function and reversible diabetes insipidus.
- Sport: not named on the WADA 2026 list.
What we’re watching
The Brazilian NoVa trial, which compares early vasopressin with later rescue use in 2,800 people with sepsis (NCT06464510). Its primary completion is expected in August 2027. We are also watching for Vasostrict label updates and for new FDA approvals of vasopressin products.